(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
Old age isn’t a modern phenomenon – many people lived long enough to grow old in the olden days, too- Taylor Swift's 'The End of an Era' docuseries: Everything you need to know, plus how to watch for less
- Australia’s post-Bondi crackdown accused of targeting pro-Palestinian voices
- Russia accidentally destroys its only way of sending astronauts to space
- The face is familiar, the name might not be. The king of "Hey, it's that guy!' roles is ready to show you his next act.
- Moldova says Russian drones violated airspace
- Brazil judge orders government to add JBS subsidiary to 'dirty list' for slavery
- Bitcoin momentum builds in Abu Dhabi as global interest surges
- Venezuelan President Maduro arrives in New York following U.S. capture: Full coverage
